» Articles » PMID: 15537338

Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1,3-diphenyl-1H- Pyrazol-5-yl)benzamides That Potentiate Receptor Function in Vivo

Abstract

This report describes the discovery of the first centrally active allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Appropriately substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides (e.g., 8) have been identified as a novel class of potent positive allosteric modulators of mGluR5 that potentiate the response to glutamate. An iterative analogue library synthesis approach provided potentiators with excellent potency and selectivity for mGluR5 (vs mGluRs 1-4, 7, 8). Compound 8q demonstrated in vivo proof of concept in an animal behavior model where known antipsychotics are active, supporting the development of new antipsychotics based on the NMDA hypofunction model for schizophrenia.

Citing Articles

Multicomponent Synthesis of New Fluorescent Boron Complexes Derived from 3-Hydroxy-1-phenyl-1-pyrazole-4-carbaldehyde.

Savickiene V, Bieliauskas A, Belyakov S, Arbaciauskiene E, Sackus A Molecules. 2024; 29(14).

PMID: 39065010 PMC: 11279739. DOI: 10.3390/molecules29143432.


The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.

Uliana D, Lisboa J, Gomes F, Grace A Biochem Pharmacol. 2024; 228:116298.

PMID: 38782077 PMC: 11410545. DOI: 10.1016/j.bcp.2024.116298.


The Impact of LY487379 or CDPPB on eNOS Expression in the Mouse Brain and the Effect of Joint Administration of Compounds with NO Releasers on MK-801- or Scopolamine-Driven Cognitive Dysfunction in Mice.

Ploska A, Siekierzycka A, Cieslik P, Dobrucki L, Kalinowski L, Wieronska J Molecules. 2024; 29(3).

PMID: 38338372 PMC: 10856750. DOI: 10.3390/molecules29030627.


Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Luessen D, Conn P Pharmacol Rev. 2022; 74(3):630-661.

PMID: 35710132 PMC: 9553119. DOI: 10.1124/pharmrev.121.000540.


Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?.

Budgett R, Bakker G, Sergeev E, Bennett K, Bradley S Front Pharmacol. 2022; 13:893422.

PMID: 35645791 PMC: 9130574. DOI: 10.3389/fphar.2022.893422.